Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Global Clinical Trials Review, 2022

GlobalData’s clinical trial report, “Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Global Clinical Trials Review, 2022″ provides an overview of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

What are the market dynamics of the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

The number of waldenstrom macroglobulinemia clinical trials conducted globally, has decreased by 22% for the period 2016-2020. The average number of patients enrolled was highest in the year 2018. As of November 2021, over 50% of trials have been sponsored by institutions followed by companies. Out of 314 completed trials, 236 trials have results and over 80% of trials reached end points. There were 196 clinical trials in progress and 314 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 93. This was due to the lack of efficacy, safety, and lack of accrual of subjects. There were 196 clinical trials in progress of which 37% (73 trials) were in Phase I study. There were 237 clinical trials in Phase II, of which 57 clinical trials were in progress for the time period of 1995-2021.

What are the top regions and countries in the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

In total there were 620 clinical trials conducted on waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), as of November 2021, of these 434 clinical trials were in North America. More than 55% of the clinical trials were conducted in North America.

Asia-Pacific: As of November 2021, in the Asia-Pacific region, China has the highest number of waldenstrom macroglobulinemia clinical trials followed by Australia, South Korea, Japan, and New Zealand.

Europe: Among the European countries, Italy has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021, followed by France, the UK, Germany, and Spain.

North America: In the country-wise analysis, the US has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021 followed by Canada and Mexico.

Middle East and Africa: Israel has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021 followed by South Africa, Saudi Arabia, and Egypt.

Central and South America: Brazil has the highest number of waldenstrom macroglobulinemia clinical trials, in the region followed by Argentina, Colombia, Chile, and Peru.

G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, The US has the highest proportion of waldenstrom macroglobulinemia in oncology clinical trials as of November 2021. In total there were 679 clinical trials conducted on waldenstrom macroglobulinemia, as of November 2021 in G7 Countries, of these 423 clinical trials were in the US. There were 131 clinical trials in progress and 273 trials are completed. The trials that are terminated/suspended or withdrawn accounted to 90. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of waldenstrom macroglobulinemia to oncology clinical trials as of November 2021. In total there were 125 clinical trials conducted on waldenstrom macroglobulinemia, as of November 2021 in E7 Countries, of these 78 clinical trials were in China. There were 60 clinical trials in progress and 22 trials were completed. The trials that were terminated/suspended or withdrawn accounted to four. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

As of November 2021, Gilead Sciences Inc has conducted the highest number of waldenstrom macroglobulinemia clinical trials followed by Takeda Pharmaceutical Co Ltd. Other major players include AbbVie Inc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co, AstraZeneca Plc, BeiGene Ltd, Amgen Inc, and Novartis AG.

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

 Scope

• The report provides a snapshot of the global clinical trials landscape.
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
• The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for un-accomplishment.
• The Report provides enrollment trends for the past five years.
• Report provides the latest news for the past three months.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.